Kazia Therapeutics (KZIA) Income towards Parent Company (2009 - 2011)

Kazia Therapeutics (KZIA) has 3 years of Income towards Parent Company data on file, last reported at -$926122.0 in Q4 2011.

• In Q4 2011, Income towards Parent Company rose 81.99% year-over-year to -$926122.0; the TTM figure through Dec 2016 stood at -$926122.0 (changed N/A YoY), while the FY2025 annual figure was -$13.3 million, up 24.87% from the prior year.
• Income towards Parent Company advanced to -$926122.0 in Q4 2011, from -$5.1 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$926122.0 in Q4 2011 and bottomed at -$5.8 million in Q4 2009.
• A 3-year average of -$3.9 million and a median of -$4.5 million in 2009 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2010 — Income towards Parent Company increased 11.52% — and 2011, when it soared 81.99%.
• Year by year, Income towards Parent Company stood at -$5.8 million in 2009, then climbed by 11.52% to -$5.1 million in 2010, then soared by 81.99% to -$926122.0 in 2011.
• The last three Income towards Parent Company figures came in at -$926122.0 (Q4 2011), -$5.1 million (Q4 2010), and -$5.8 million (Q4 2009), per Business Quant data.

Peer Comparison